Operational performance shows improvement, with EBITDA rising 11 percent.
Sun Pharmaceuticals reported a net loss of Rs 218 crore for the September quarter on the back of one-time loss of Rs 1,214.38 crore. The company had posted a net profit of Rs 912.12 crore during the corresponding quarter of last year.
The revenue stood at Rs 6,937.63 crore for quarter under review, up from Rs 6,650.34 crore reported during last year. This implies a rise of 4 percent year on year.
At an operating level, the earnings before interest, taxes, depreciation and amortization (EBITDA) was posted at Rs 1,531.1 crore, a rise of 11 percent to previous year’s operating profit of Rs 1,375.5 crore.
The operating margin was reported at 22.1 percent against 20.7 percent last year.
“We did not review the financial results and other financial information, in respect of 24 subsidiaries including their associates and joint ventures, whose lnd AS financial results, without giving effect to elimination of intra-group transactions, include total assets of Rs 64,229.74 crore as of September 30, 2018, and total revenues of Rs 4,830.24 crore and Rs 10,125.72 crore for the quarter and the period ended on that date,” the company said in an exchange filing.
At the close of market hours, Sun Pharmaceutical Industries was quoting at Rs 561.70, down Rs 27.85, or 4.72 percent, on the BSE. It touched an intraday high of Rs 594.90 and an intraday low of Rs 556.05.
